Loading...
•
Jun 30, 2024
Amicus Therapeutics Q2 2024 Earnings Report
Amicus Therapeutics reported strong revenue growth and achieved non-GAAP profitability.
Key Takeaways
Amicus Therapeutics announced Q2 2024 financial results, reporting a total revenue of $126.7 million, a 34% increase year-over-year. The company achieved non-GAAP profitability in Q2 and H1 2024 and raised its 2024 total revenue growth guidance to 26%-31% at CER.
Total revenue for Q2 2024 reached $126.7 million, a 34% increase year-over-year.
Galafold revenue in Q2 2024 was $110.8 million, up 17% year-over-year.
Pombiliti + Opfolda revenue in Q2 2024 totaled $15.9 million, up 44% from Q1 2024.
The company raised its 2024 total revenue growth guidance to 26%-31% at CER.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.comPombiliti + Opfolda Revenue
CapyFin.com Forward Guidance
Amicus Therapeutics raised 2024 Total Revenue Growth Guidance to 26%-31% at CER and narrowed non-GAAP Operating Expense Guidance to $345M to $360M.
Revenue & Expenses
Visualization of income flow from segment revenue to net income